Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4424002 | 0.98 | GNAO1 (0.51) | GNAO1CYP1A2RAD52CHRM5ADRA2C | |
| SCHEMBL640737 | 0.98 | GNAO1 (0.50) | GNAO1CYP1A2RAD52CHRM5ADRA2C | |
| SCHEMBL13660827 | 0.96 | GNAO1 (0.46) | GNAO1CYP1A2RAD52CHRM5ADRA2C | |
| Hydrochloric Acid SCHEMBL6150599 | 0.96 | GNAO1 (0.53) | GNAO1CYP1A2RAD52CHRM5ADRA2C | |
| SCHEMBL13661478 | 0.94 | GNAO1 (0.45) | GNAO1CYP1A2RAD52CHRM5ADRA2C | |
| SCHEMBL3440711 | 0.94 | GNAO1 (0.50) | GNAO1CYP1A2RAD52GNAI3GNAI1 | |
| SCHEMBL13660823 | 0.89 | CHRM5 (0.50) | GNAO1CYP1A2RAD52CHRM5ADRA2C | |
| SCHEMBL7122133 | 0.88 | GNAO1 (0.54) | GNAO1RAD52GNAI3GNAI1CXCR4 | |
| SCHEMBL9824369 | 0.88 | GNAO1 (0.54) | GNAO1RAD52GNAI3GNAI1CXCR4 | |
| SCHEMBL7462427 | 0.88 | CYP1A2 (0.43) | GNAO1CYP1A2RAD52CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401370-A1 | AMINO (METH)ACRYLATES | Allnex Belgium S.A. (BE) | 2018-11-14 | — | — | EP | claimed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12528948-B2 | Amino (meth)acrylates | ALLNEX BELGIUM S.A. (BE) | 2026-01-20 | — | — | US | disclosed |
| CN-119823124-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115279370-B | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-111295373-B | Compositions and methods for treating brain injury | 阿泽凡药物公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116285486-A | Radiation-curable amino (methyl) acrylate resin, ink composition and application thereof | 长兴特殊材料（珠海）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-0720602-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008535-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1995-03-30 | — | — | WO | disclosed |
| EP-0306698-B1 | CONDENSED DIAZEPINONES, PROCESSES FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1992-03-25 | — | — | EP | disclosed |
| EP-0273239-B1 | CONDENSED DIAZEPINONES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1991-03-06 | — | — | EP | disclosed |
| US-4931436-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1990-06-05 | — | — | US | disclosed |
| US-4873236-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1989-10-10 | — | — | US | disclosed |
| EP-0306698-A1 | Condensed diazepinones, processes for their preparation, and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1989-03-15 | — | — | EP | disclosed |
| EP-0273239-A1 | Condensed diazepinones, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1988-07-06 | — | — | EP | disclosed |
| US-4345071-A | AZIDOALKYL-HETEROCYCLIC AMIDINE INTERMEDIATES | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1982-08-17 | — | — | US | disclosed |
| US-4229443-A | Derivatives of penicillanic acid | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | GNAO1 2970/4885CYP1A2 2732/4885RAD52 2776/4885 |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | GNAO1 2590/4885CYP1A2 4579/4885RAD52 1024/4885 |
| US-12528948-B2 | Amino (meth)acrylates | MAT2B, MAT1A, MMAB | GNAO1 2838/4885CYP1A2 1516/4885RAD52 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.